A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2018
Price : $35 *
At a glance
- Drugs INXN 2001 (Primary) ; Palifosfamide (Primary) ; Veledimex (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ZIOPHARM Oncology
- 31 Aug 2018 Biomarkers information updated
- 18 Sep 2015 According to Ziopharm media release, results presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
- 05 Feb 2015 AS per NCT no of tt. arms changed from 3 to 2 and veledimex is added in tt. arms given in combination with Ad-RTS-hIL-12.